

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 14, 2025

CD25

RRID:AB_394509

Type: Antibody

Proper Citation

(BD Biosciences Cat# 552880, RRID:AB_394509)

Antibody Information

URL: http://antibodyregistry.org/AB_394509

Proper Citation: (BD Biosciences Cat# 552880, RRID:AB_394509)

Target Antigen: CD25 (IL-2 Receptor ?)

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry
Info: Used by Czech Centre for Phenogenomics

Antibody Name: CD25

Description: This monoclonal targets CD25 (IL-2 Receptor ?)

Target Organism: mouse

Antibody ID: AB_394509

Vendor: BD Biosciences

Catalog Number: 552880

Record Creation Time: 20231110T081126+0000

Record Last Update: 20241115T121252+0000

Ratings and Alerts

- Used by Czech Centre for Phenogenomics - Czech Centre for Phenogenomics
<https://www.phenogenomics.cz/>

No alerts have been found for CD25.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Cao S, et al. (2024) Glycosylation-modified antigens as a tolerance-inducing vaccine platform prevent anaphylaxis in a pre-clinical model of food allergy. *Cell reports. Medicine*, 5(1), 101346.

Meza-Perez S, et al. (2024) Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine. *Cell host & microbe*, 32(7), 1177.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Yadavilli S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. *Cancer research communications*, 3(8), 1564.

Fernández-Pisonero I, et al. (2022) A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors. *Cell reports*, 38(11), 110522.

Xiang H, et al. (2022) Vps33B controls Treg cell suppressive function through inhibiting lysosomal nutrient sensing complex-mediated mTORC1 activation. *Cell reports*, 39(11), 110943.

Dignum T, et al. (2021) Multipotent progenitors and hematopoietic stem cells arise independently from hemogenic endothelium in the mouse embryo. *Cell reports*, 36(11), 109675.

Matias MI, et al. (2021) Regulatory T cell differentiation is controlled by ?KG-induced alterations in mitochondrial metabolism and lipid homeostasis. *Cell reports*, 37(5), 109911.

Kumari R, et al. (2021) MicroRNA miR-29c regulates RAG1 expression and modulates V(D)J recombination during B cell development. *Cell reports*, 36(2), 109390.

Kitamoto S, et al. (2020) The Intermucosal Connection between the Mouth and Gut in

Commensal Pathobiont-Driven Colitis. *Cell*, 182(2), 447.

Siamishi I, et al. (2020) Lymphocyte-Specific Function of the DNA Polymerase Epsilon Subunit Pole3 Revealed by Neomorphic Alleles. *Cell reports*, 31(11), 107756.

Pei W, et al. (2020) Resolving Fates and Single-Cell Transcriptomes of Hematopoietic Stem Cell Clones by PolyloxExpress Barcoding. *Cell stem cell*, 27(3), 383.

Daglas M, et al. (2019) Activated CD8+ T Cells Cause Long-Term Neurological Impairment after Traumatic Brain Injury in Mice. *Cell reports*, 29(5), 1178.

Adoue V, et al. (2019) The Histone Methyltransferase SETDB1 Controls T Helper Cell Lineage Integrity by Repressing Endogenous Retroviruses. *Immunity*, 50(3), 629.

Bianchi JJ, et al. (2019) Breakage-Fusion-Bridge Events Trigger Complex Genome Rearrangements and Amplifications in Developmentally Arrested T Cell Lymphomas. *Cell reports*, 27(10), 2847.

Yen WF, et al. (2019) Distinct Requirements of CHD4 during B Cell Development and Antibody Response. *Cell reports*, 27(5), 1472.

Alter C, et al. (2019) A2bR-dependent signaling alters immune cell composition and enhances IL-6 formation in the ischemic heart. *American journal of physiology. Heart and circulatory physiology*, 317(1), H190.

Perrot I, et al. (2019) Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. *Cell reports*, 27(8), 2411.